Literature DB >> 28340374

Ebola virus persistence as a new focus in clinical research.

Katie Caviness1, Jens H Kuhn2, Gustavo Palacios3.   

Abstract

Ebola virus (EBOV) causes severe acute human disease with high lethality. Viremia is typical during the acute disease phase. However, EBOV RNA can remain detectable in immune-privileged tissues for prolonged periods of time after clearance from the blood, suggesting EBOV may persist during convalescence and thereafter. Eliminating persistent EBOV is important to ensure full recovery of survivors and decrease the risk of outbreak re-ignition caused by EBOV spread from apparently healthy survivors to naive contacts. Here, we review prior evidence of EBOV persistence and explore the tools needed for the development of model systems to understand persistence.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28340374     DOI: 10.1016/j.coviro.2017.02.006

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  8 in total

1.  Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection.

Authors:  Sean Ekins; Mary A Lingerfelt; Jason E Comer; Alexander N Freiberg; Jon C Mirsalis; Kathleen O'Loughlin; Anush Harutyunyan; Claire McFarlane; Carol E Green; Peter B Madrid
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

Review 2.  An update on ocular complications of Ebola virus disease.

Authors:  Jessica G Shantha; Ian Crozier; Steven Yeh
Journal:  Curr Opin Ophthalmol       Date:  2017-11       Impact factor: 3.761

3.  Association of persistent wild-type measles virus RNA with long-term humoral immunity in rhesus macaques.

Authors:  Ashley N Nelson; Wen-Hsuan W Lin; Rupak Shivakoti; Nicole E Putnam; Lisa Mangus; Robert J Adams; Debra Hauer; Victoria K Baxter; Diane E Griffin
Journal:  JCI Insight       Date:  2020-02-13

4.  Novel Stable Ebola Virus Minigenome Replicon Reveals Remarkable Stability of the Viral Genome.

Authors:  Wanyin Tao; Tianyu Gan; Mingzhe Guo; Yongfen Xu; Jin Zhong
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

5.  Why does viral RNA sometimes persist after recovery from acute infections?

Authors:  Diane E Griffin
Journal:  PLoS Biol       Date:  2022-06-01       Impact factor: 9.593

6.  Histology, immunohistochemistry, and in situ hybridization reveal overlooked Ebola virus target tissues in the Ebola virus disease guinea pig model.

Authors:  Timothy K Cooper; Louis Huzella; Joshua C Johnson; Oscar Rojas; Sri Yellayi; Mei G Sun; Sina Bavari; Amanda Bonilla; Randy Hart; Peter B Jahrling; Jens H Kuhn; Xiankun Zeng
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

7.  An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells.

Authors:  Yingyun Cai; Shuiqing Yu; Xiaoli Chi; Sheli R Radoshitzky; Jens H Kuhn; Edward A Berger
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

8.  Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection.

Authors:  Thomas R Lane; Christopher Massey; Jason E Comer; Manu Anantpadma; Joel S Freundlich; Robert A Davey; Peter B Madrid; Sean Ekins
Journal:  PLoS Negl Trop Dis       Date:  2019-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.